Open Label Study of Fostamatinib in the Treatment of IgA Nephropathy
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Phase 2, multi-center, open label extension study to evaluate 2 dose regimens of fostamatinib
in approximately 25 subjects. The study will consist of 11 visits over 15 months.